We then performed cell migration and proliferation assays using CAR‐T cells targeting chondroitin sulfate proteoglycan 4 antigen (CSPG4‐CAR‐T) that we previously identified as a clinically relevant target in GBM.16 Here, CSPG4 is linked to glioblastoma.